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Abstract
Background: Malaria in pregnancy can expose the fetus to malaria-infected erythrocytes or their soluble products, thereby
stimulating T and B cell immune responses to malaria blood stage antigens. We hypothesized that fetal immune priming, or
malaria exposure in the absence of priming (putative tolerance), affects the child’s susceptibility to subsequent malaria
infections.
Methods and Findings: We conducted a prospective birth cohort study of 586 newborns residing in a malaria-holoendemic
area of Kenya who were examined biannually to age 3 years for malaria infection, and whose malaria-specific cellular and
humoral immune responses were assessed. Newborns were classified as (i) sensitized (and thus exposed), as demonstrated
by IFNc, IL-2, IL-13, and/or IL-5 production by cord blood mononuclear cells (CBMCs) to malaria blood stage antigens,
indicative of in utero priming (n=246), (ii) exposed not sensitized (mother Plasmodium falciparum [Pf]+ and no CBMC
production of IFNc, IL-2, IL-13, and/or IL-5, n=120), or (iii) not exposed (mother Pf2, no CBMC reactivity, n=220). Exposed
not sensitized children had evidence for prenatal immune experience demonstrated by increased IL-10 production and
partial reversal of malaria antigen-specific hyporesponsiveness with IL-2+IL-15, indicative of immune tolerance. Relative risk
data showed that the putatively tolerant children had a 1.61 (95% confidence interval [CI] 1.10–2.43; p=0.024) and 1.34
(95% CI 0.95–1.87; p=0.097) greater risk for malaria infection based on light microscopy (LM) or PCR diagnosis, respectively,
compared to the not-exposed group, and a 1.41 (95%CI 0.97–2.07, p=0.074) and 1.39 (95%CI 0.99–2.07, p=0.053) greater
risk of infection based on LM or PCR diagnosis, respectively, compared to the sensitized group. Putatively tolerant children
had an average of 0.5 g/dl lower hemoglobin levels (p=0.01) compared to the other two groups. Exposed not sensitized
children also had 2- to 3-fold lower frequency of malaria antigen-driven IFNc and/or IL-2 production (p,0.001) and higher
IL-10 release (p,0.001) at 6-month follow-ups, when compared to sensitized and not-exposed children. Malaria blood
stage–specific IgG antibody levels were similar among the three groups.
Conclusions: These results show that a subset of children exposed to malaria in utero acquire a tolerant phenotype to
blood-stage antigens that persists into childhood and is associated with an increased susceptibility to malaria infection and
anemia. This finding could have important implications for malaria vaccination of children residing in endemic areas.
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Falciparum malaria is one of the most important pediatric
infectious diseases in sub-Saharan Africa, where it is estimated to
kill at least 1 million children per year. In areas where malaria
transmission is stable, infants and children typically experience
clinical morbidity and high blood stage parasite densities. Infants
up to 6 months old appear to be relatively resistant to clinical
malaria and high-density parasitemia, while children between 6
and 36 months of age appear to have increased susceptibility to
these clinical and parasitological outcomes [1]. Although evidence
supporting a direct role for passively acquired maternal IgG
antibodies in mediating protection against infant malaria is
inconsistent [2], epidemiologic studies show that malaria suscep-
tibility increases after maternal antibodies have waned but before
immunity to blood-stage Plasmodium falciparum (Pf) can develop due
to repeated infections [3]. Knowledge of the immune mechanisms
underlying changes in infant malaria susceptibility may have
important implications, not only for the fundamental understand-
ing of human malaria immunobiology, but also for evaluation of
the efficacy of future malaria vaccine initiatives with this age
group.
The physiologic and immunologic effects of maternal malaria
infection on the fetus complicate the acquisition of anti-malaria
immunity in children. Pf-infected erythrocytes have the propensity
to sequester in the intervillous blood of the placenta, a condition
referred to as placental malaria. Placental malaria is most common
in women with their first or second pregnancy, seemingly due to
the lack of acquired immunity to Pf clones that preferentially bind
to the placental vasculature [4,5]. In this context, the fetus may be
exposed to soluble malaria antigens or infected erythrocytes that
gain access to the fetal circulation after crossing the placenta.
Although it is not feasible to document this process in vivo, indirect
evidence supporting its occurrence includes the demonstration of
T and B cell responses to crude schizont extracts and blood-stage
antigens in cord blood lymphocytes, a cell population that
represents circulating fetal lymphocytes present at the time of
birth [6–9]. The consequences of this in utero immune experience
on infant malaria immunity are not known, particularly whether it
accelerates the development of protective antibodies or whether
cellular immune responses are inhibited by virtue of sensitization
and/or subsequent immune tolerance mechanisms.
The significance of fetal malaria experience is underscored by
epidemiologic studies suggesting that offspring of women with
placental malaria are more susceptible to malaria during infancy
than those of mothers without placental malaria [10–12]. These
studies, however, do not explore the mechanisms for this increased
susceptibility. Although the presence of placental malaria or
malaria during pregnancy is associated with fetal priming to
malaria blood stage antigens [7–9,13,14], some offspring fail to
acquire protective responses in the presence of maternal malaria,
suggesting the fetus may acquire immune tolerance [15,16].
Offspring of women with malaria at delivery, for example, have
evidence for impaired acquisition of malaria-specific antibodies
[17], as well as reduced levels of functional antibodies that inhibit
invasion of erythrocytes by the membrane-anchored MSP119,a
protein required for entry of the parasite into red blood cells [18].
It is unknown whether prenatal exposure to malaria results in
persistent expansion or suppression of malaria blood stage–specific
cellular or humoral immunity, and whether this affects infant
susceptibility to malaria infection and disease.
We describe here the results of a prospective cohort study of
infants born in a malaria-holoendemic area of Kenya. The study
was designed to test the hypothesis that prenatal malaria
experience, reflected by maternal malaria infection at parturition
and neonatal cord blood T cell sensitization to several malaria
blood stage invasion ligands, could influence susceptibility to
malaria infection and risk of anemia in the first 3 years of life. To
understand the mechanism associated with the altered risk for
malaria, we measured whether this prenatal experience influences
acquisition of cellular and humoral immune responses to these
same invasion ligands, as measured biannually in children during
the first 3 years of life. Merozoite surface protein 1 (MSP1) is the
most abundant merozoite protein and a leading malaria vaccine
candidate [19,20]. PfP0 is also a merozoite surface protein,
antibodies to which block Pf erythrocyte invasion in vitro [21,22].
Apical membrane antigen 1 (AMA1) and the F-2 region of the
175 kDa erythrocyte binding antigen (EBA-175) are proteins
released from rhoptries or micronemes, organelles within the
merozoite, following initial merozoite attachment to erythrocytes
[23–25]. These proteins were studied because they represent
important vaccine candidates to which artificially or naturally
acquired antibodies have been shown to block Pf erythrocyte
invasion in vitro; in non-human primates, immunization with
them produces partial immunity to blood-stage infection [25–27].
Methods
Study Participants and Study Design
Approval for the study was obtained from the Kenya Medical
Research Institute National Ethical Review Committee and the
Institutional Review Board for Human Studies at Case Western
Reserve University. Mothers provided witnessed written informed
consent for participation and assent for their infants. All women
included in the study were screened for HIV as part of a volunteer
counseling and testing (VCT) program supported by the
International Center for Reproductive Health and the Kenyan
Ministry of Health starting in 2002. Counseling and perinatal
treatment with nevaripine was provided through this program. All
HIV results were kept strictly confidential. For women recruited
before 2002 who had not participated in the VCT program, and
following written informed consent, stored frozen plasma samples
(at 280uC) from mothers were examined by HIV-ELISA as
described [28]. For offspring of women who tested positive for
HIV, testing for the virus was performed on frozen samples that
had been collected in follow-up visits with their mothers.
Pregnant women were recruited from the antenatal clinic at
Msambweni District Hospital, Kwale District in Coast Province,
Kenya. They underwent a detailed questionnaire that queried
their education level, spouse’s occupation, and household income.
Malaria transmission in this area is stable, with seasonal variation
related to rainfall [29]. Women enrolled in the study were given
malaria prophylaxis consisting of single-dose sulfadoxine–pyri-
methamine (SP) at the beginning of the second and third trimesters
of pregnancy, in accordance with recommendations from the
Kenya Ministry of Health. Paired maternal venous blood,
placental intervillous blood, and umbilical cord blood from the
newborns were collected at the time of birth. Cord blood was
collected as described [15] and the absence of placental alkaline
phosphatase (PLAP) indicated the sample did not have significant
contamination by maternal blood [30]. Infant venous blood
samples (,5 ml) were collected beginning at 6 mo of age and
every 6 mo thereafter until age 36 mo. Plasma was stored at
280uC until antibody assays were performed. Cellular immune
responses at birth and during subsequent follow-ups were
performed on fresh cells.
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Maternal venous blood, intervillous placental blood, and cord
blood were examined for malaria infection status by two methods.
In the LM method, thick and thin blood smears were prepared,
fixed in methanol, stained with Giemsa, and examined by light
microscopy (LM) for Pf-infected erythrocytes in 100 high-powered
fields. The density of parasitemia was expressed as the number of
asexual P. falciparum per microliter of blood, assuming a leukocyte
count of 8,000/ml. In the PCR method, DNA was extracted from
200 ml of whole intervillous blood and the red cell pellet of
anticoagulated maternal and cord blood (Qiagen). Real-time
quantitative PCR (RTQPCR) was performed, with 2.5 ml of DNA
used as a template for amplification of the multicopy Pf 18S small
subunit ribosomal RNA gene [31,32]. The increased sensitivity of
the RTQPCR assay in comparison to LM analysis for Pf malaria
has been described in detail [31]. A newborn was considered
‘‘exposed’’ to malaria in utero if one or more of the blood smear
preparations or RTQPCR results from the various compartments
were positive, and/or CBMC had a recall response to malaria
blood stage antigens. A newborn was considered to be ‘‘not
exposed’’ when both diagnostic tests were negative for all three
blood compartments and CBMC lacked a recall response to
malaria blood stage antigen.
Helminth Infections and Hemoglobin
Stool and urine were obtained at delivery and examined for the
presence of intestinal helminths and schistosome ova, respectively,
as described [33]. Night blood samples were obtained from
pregnant women prior to delivery, and 1 ml of heparinized blood
filtered for the presence of Wuchereria bancrofti microfilariae as
described [34]. W. bancrofti was also assessed by a circulating antigen
assayusing stored frozen plasmasamples collectedatdelivery,based
on the Og4C3 antigen detection assay (TropBioMed). Samples
were obtained during follow-up periods if participants were unable
to provide samples at delivery. Women infected with intestinal
helminths or schistosomes were treated with mebendazole (500 mg
in a single dose) or praziquantel (40 mg/kg in a divided dose),
respectively, according to the Kenyan Ministry of Health
recommendations after delivery. No specific therapy was given for
W. bancrofti infections, because a district-wide treatment program
was started during the study (October 2002) as part of the WHO-
sponsored global program to eliminate filariasis. Hemoglobin levels
were assessed from fresh peripheral blood samples in children using
the HemoCue system (HemoCue).
Antigens, Mitogens, and Recombinant Cytokines
For the T cell studies in cord blood and peripheral venous
blood, both peptides and recombinant antigens were used. For
MSP1, two peptides were used that correspond to well-
characterized T cell epitopes within the C-terminal 83 kDa
fragment of MSP1 (GYRKPLDNIKDNVGKMEDYIKK, codons
250–271; KLNSLNNPHNVLQNFSVFFNK, codons 101–121)
[15]. Three peptides were used corresponding to N- and C-
terminal regions of PfP0, denoted N1 (DNVGSNQMAS-
VRKSLR; codon 33–48), N2 (SVRKSLRGKATILMGKNT;
codon 42–59), and C1 (AKADEPKKEEAKKVE; codon 285–
299) as previously described [35]. The peptides were synthesized
and purified to .95% (ResGen) and subjected to analysis by
MHC Class-II Binding Peptide Prediction algorithms (Propred
and Tepitope). They were found to have broad binding specificity
to many MHC class II alleles including DRB1*0401, DRB1*0101,
and DRB1*1501, which are common in Kenya [36]. Recombinant
EBA175 (codons 144–753) corresponding to region II (the binding
domain to sialic acid on erythrocytes [23]) was expressed in Pichia
[37]. The MSP142 was expressed in E. coli and properly refolded as
described [38]. Tetanus toxoid was obtained from the Massachu-
setts Department of Health and used at a dilution of 1:200.
Phorbol 12-myristate 13-acetate (PMA) plus ionomycin (Calbio-
chem) were used as positive mitogen controls in parallel cultures
for cytokine assays. For lymphocyte proliferation assays performed
on a subset of CBMC, the mitogen control was phytohemagglu-
tinin (PHA, Sigma) at 5 mg/ml.
Cord and Peripheral Blood Lymphocyte Cultures
Cord blood was obtained from the umbilical vein immediately
after delivery and anticoagulated with heparin. Similarly, maternal
peripheral venous blood was obtained by venipucture and
anticoagulated with heparin. CBMCs and peripheral blood
mononuclear cells (PBMCs) were isolated from the freshly
obtained blood by density gradient centrifugation on Ficoll-
Hypaque as described [15]. CBMCs were cultured at a density of
2610
6/ml in a total volume of 0.5 ml in duplicate in 48-well flat-
bottomed plates (Costar), in RPMI-1640 supplemented with heat-
inactivated 10% autologous plasma, 4 mM L-glutamine, 25 mM
HEPES, and 80 mg/ml gentamicin (Biowhittaker). For lymphocyte
proliferation studies, CBMCs were cultured at 2610
6/ml in a total
volume of 200 ml in triplicate.
In preliminary studies, heat-inactivated autologous plasma was
not suppressive when compared to serum-free medium in activated
lymphocyte cultures (unpublished data). By contrast, we occasion-
ally observed high background and nonspecific lymphocyte
reactivity using fetal calf serum or pooled human sera (unpublished
data). For PBMC cultures 10% fetal calf serum was used instead of
autologous plasma (Hyclone; with low reactivity). Lymphocyte
cultures were also performed at a density of 1610
6/ml in a total
volume of 200 ml in triplicate for both cytokine production and
lymphocyte proliferation assays. For lymphocyte proliferation
studies 1 mCi of
3H-thymidine (New England Nuclear) was added
to each culture and harvested 16 h later as described [39].
3H-
thymidine was measured with a beta-counter (Packard Matrix).
For CBMCs the following culture conditions were used:
medium alone (negative control); 10 mg/ml MSP1 P2 and P3
peptides; 10 mg/ml PfP0 N1, N2, or C1 peptide; 5 mg/ml
EBA175; and PMA (50 pg/ml) plus ionomycin (1 mg/ml) in
duplicate. CBMCs were cultured with individual peptides except
when there were insufficient cells and MSP1 and PfP0 peptides
were pooled. For PBMCs, MSP1 and PfP0 peptides were pooled
for all participants, because of limited blood volume. In a subset of
children with larger lymphocyte recoveries, peptides were cultured
individually. Pooling peptides in CBMC or PBMC cultures did not
affect the levels of antigen-induced cytokine production or
lymphocyte proliferation (unpublished data). All culture superna-
tants were immediately frozen at 280uC following culture.
In a subset of CBMCs (i.e., cord blood collected from all
deliveries September through November 2002), recombinant
human IL-2 and IL-15 (10 U/ml, BD Biosciences) were added
to parallel cultures, with medium alone or with malaria antigens,
to assess the effect of these cytokines on reversing immune
hyporesponsiveness. Lymphocyte proliferation responses, with
addition of rIL-2+rIL-15 and malaria antigens, divided by
lymphocytes cultured with rIL-2+rIL-15 alone (i.e., malaria
antigen+rIL-2+rIL-15/rIL-2+rIL-15), were calculated, and we
designated a positive response when this ratio exceeded 2.
Measurement of Cytokines and Criteria for a Positive
Response to Malaria Antigens by CBMCs
Quantification of IFNc, IL-5, IL-13, IL-2, and IL-10 was
performed on culture supernatants collected at 72 h by ELISA
Prenatal Exposure and Malaria Risk
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standard curves based on recombinant lymphokines [40].
Antibody pairs for capture and detection (all biotinylated) for the
cytokines studied were as follows: IL-5, 18051D and 18522D (BD-
Pharmingen); IFNc, M-700A and M-701B (Endogen); IL-13, P-
130-E and M-130-B (Endogen); IL-2, MAB-602 and BAF-202
(R&D Systems); IL-10, 18551D and 18652D (BD-Pharmingen). A
positive response was scored when both of the following criteria
were fulfilled: (1) a net value for antigen-stimulated cells at least 2-
fold greater than that of parallel cultures containing media alone.
If cytokine production was not detectable in the negative control
cultures, then .40 pg/ml cytokine was considered to be a positive
response; and (2) responses to two or more malaria antigens.
IFNc ELISPOT for both CBMCs and PBMCs was also
performed at 48 h as described for all samples [41]. A positive
response was scored when one of the following conditions were
met: (1) $4 IFNc-secreting cells/4610
5 CBMCs or PBMCs in
response to at least two malaria antigens when no IFNc-secreting
cells were present in negative control wells (media alone); (2) in
cases where IFNc-secreting cells were observed in negative control
wells, the number of spots generated by antigen-driven cord blood
lymphocytes (CBLs) was at least 2-fold greater. Based on these
criteria, no malaria antigen-driven IFNc-secreting cells were
detected in CBMC from 16 healthy North American newborns
or PBMCs from ten malaria-naı ¨ve adults.
Measurement of IgG in Plasma to MSP142, AMA1, and
EBA175-Region II
IgG antibodies to recombinant Pf MSP142 (3D7 and FVO
alleles) and AMA1 (3D7 and FVO alleles) and region II EBA175
were measured by ELISA as described previously [42,43]. Briefly,
Immunolon 4 plates were coated with 0.1 mg/ml MSP142 or
AMA1, and 0.2 mg/ml of EBA175 in PBS. Plates were
subsequently blocked with 3% bovine albumin in PBS (Sigma)
to which 1:200 final dilution of cord or peripheral blood plasma
was added and incubated at 4uC overnight. Plates were
subsequently washed, and a 1:2,000 dilution of goat anti-human
IgG conjugated alkaline phosphatase added and incubated for 2 h
at 37uC (H&L recognition, Jackson ImmunoResearch). A pool of
ten cord blood plasma samples with high antibody reactivity was
used as a standard, with a 1:200 dilution used as high standard and
given the arbitrary value of 100. The pooled plasma was
subsequently serially 2-fold diluted eight times to generate the
standard curve. A positive control plasma sample with IgG
antibodies that recognized all recombinant antigens tested was also
added to each plate. Plasma from nine North American adults
never exposed to malaria was used as the negative control. Positive
values were greater than the mean+3 standard deviations (SDs) of
the value of the individual negative control plasma samples.
Statistics
All statistical analysis was performed using SAS version 9.1.
Statistical comparisons of continuous variables according to
prenatal malaria exposure were performed using the Mann-
Whitney test, Kruskal Wallis test, or Student’s t-test of log-
transformed values, depending on data distribution and number of
exposure categories analyzed. Categorical outcomes were ana-
lyzed using the Chi-square test. Repeated measures of categorical
outcomes (i.e., infection status, cytokine outcomes, and antibody
responses) were analyzed with generalized estimating equations
[44] using the PROC GENMOD procedure with a binomial
distribution for the response variable with a logit link function.
Repeated continuous outcomes (i.e., parasite density and hemo-
globin) were analyzed with repeated measure models using the
PROC MIXED procedure, as previously described [45]. These
methods allowed us to accommodate repeat observations among
the same children. Time was included as a linear variable and its
interaction term with prenatal malaria exposure category was
evaluated for rate of change in outcomes over time. Parasite
counts were log-transformed to normalize the data. All models
included the dichotomous covariates of season and study site. The
auto-regressive covariance structure was used for both sets of
repeated measure analyses as this structure gave the best fit based
on Akaike’s information criterion, the corrected Akaike’s infor-
mation criterion, and the Bayesian information criterion as
provided in the SAS 9.1 output.
Results
Study Population and Classification of Prenatal Immune
Status
An overview of the enrollment and follow-up of the participants
is presented in Figure 1. A total of 700 mother–newborn pairs
were recruited between 2000 and 2003 with 586 children (83%)
enrolled in the birth cohort. One hundred fourteen children were
excluded because of insufficient CBMC collection, non-viable
CBMCs (no response to mitogens), or failure to return for any
follow-up visits. (The major reason for failure to return for any
visits was emigration from the study area). The average number of
follow-up visits was 3.5 out of 5.3 potential visits, or 66% follow-
up. Children recruited late in the study did not have a full 3 y of
follow-up.
Newborns were categorized as ‘‘exposed not sensitized,’’
‘‘exposed sensitized,’’ and ‘‘not exposed’’ groups (Table 1).
Exposed not sensitized infants were defined as offspring of
malaria-infected pregnant women, but lacking evidence for fetal
priming. Exposed sensitized infants were defined as showing
cytokine production to malaria-blood stage antigens by CBMCs as
described in Methods. Mothers of all but 43 sensitized newborns
had malaria at delivery. Lymphocyte proliferation was not
measured in all CBMCs and therefore not used as an indicator
of fetal priming. Malaria antigen–driven IL-10 production alone
was not considered a criterion for fetal priming because non-T
cells can generate IL-10. The not-exposed group included
offspring of pregnant women who had no evidence of malaria,
and who did not have detectable priming to malaria antigens in
cord blood.
The demographic characteristics of the three groups are also
shown in Table 1. Mothers of newborns who were ‘‘exposed’’ to
malaria at birth (sensitized and not sensitized) were slightly
younger than mothers of newborns who were ‘‘not exposed’’.
Almost half of the exposed not sensitized children (49%) had
primigravid mothers, a proportion significantly greater than with
mothers of not-exposed offspring (32%). Although women and
their newborns were enrolled just prior to delivery, antenatal clinic
records were available for many women. Women presented for
their first antenatal clinical visit on the average of 4–5 wk before
delivery, which was similar between the study groups. According
to Kenyan Ministry of Health Guidelines, a single prophylactic
dose of SP should be administered at the beginning of the second
and third trimester and not less than one month before expected
date of delivery. Since we did not record whether women received
SP or not, we cannot state with certainty whether there was a
difference in malaria prophylaxis between groups. The observa-
tion, however, that the approximate gestational age at first
antenatal clinic attendance between the groups was similar
suggests that the amount of malaria chemoprophylaxis between
groups is unlikely to be markedly different. The proportion of
Prenatal Exposure and Malaria Risk
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groups (Table 1). The socioeconomic status, as determined by
highest education level attained by both parents, household
income, and type of parental employment, was similar with
respect to exposed not sensitized children compared to the
sensitized group (p=0.23, p=0.11, and p=0.37 respectively) and
not-exposed group (p=0.54, p=0.091, and p=0.28 respectively).
The proportion of mothers with HIV or helminth coinfections is
also shown in Table 1. Overall 8.4% (n=39) of 464 mothers tested
were HIV positive. Mothers of the exposed not sensitized group
Figure 1. Flow diagram of birth cohort study.
doi:10.1371/journal.pmed.1000116.g001
Table 1. Demographic characteristics of maternal–fetal pairs according to newborn malaria exposure status and cord blood T cell
responses to MSP1, PfP0, and EBA-175.
Newborn Category Exposed Not Sensitized Exposed Sensitized Not Exposed p-Value
Maternal/newborn infection with malaria
a Yes Yes/no
b No —
Newborn T cell response to malaria antigens No Yes No —
Number of children 120 246 220 —
Males/females 60/60 133/113 117/103 0.50
c, 0.65
d
Average age of mother at delivery (y) 25.3 25.9 26.4 0.61
c, 0.19
d
Primigravida/multigravida mothers 39/80 (49%) 66/178 (37%) 53/165 (32%) 0.10
c, 0.02
d
Weeks of first antenatal clinic visit prior to delivery
(average, range)
5.3 (1–20) 4.1 (1–18) 4.5 (1–16) 0.16
c, 0.30
d
Reported bednet use in home 13% 15% 17% 0.88
c, 0.58
d
HIV-positive women (n=464 tested) 13/99 (13.1%) 17/200 (8.5%) 9/165 (5.5%) 0.22
c, 0.04
d
HIV-positive offspring 4/13 4/17 3/9 0.70
c, 1.0
d
Proportion of women with schistosomiasis 11/89 (12.3%) 24/214 (11.2%) 26/169 (15.3%) 0.84
c, 0.58
d
Proportion of women with lymphatic filariasis 31/80 (38.8%) 79/163 (48.5%) 77/138 (55.8%) 0.17
c, 0.02
d
Proportion of women with hookworm 37/62 (60.0%) 91/143 (63.6%) 55/137 (40.1%) 0.64
c, 0.01
d
aMaternal/newborn Pf infection was assessed by either LM and/or RTQPCR detection of parasites in maternal, cord, and/or intervillous placental blood.
bForty-three of the individuals in this group had T cell responses, but without maternal/newborn malaria infection at delivery.
cp-Value of exposed not sensitized compared to exposed sensitized group.
dp-Value of exposed not sensitized compared to not exposed group.
doi:10.1371/journal.pmed.1000116.t001
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HIV was transmitted to 11 offspring (28%), with a similar
proportion of HIV positive offspring in each group (Table 1). The
portion of helminth-infected women was similar among the three
groups except that mothers of the not exposed group were more
likely to be infected with lymphatic filariasis, but had lower rates of
hookworm infections.
Exposed Not Sensitized Newborns Have Evidence of T
Cell Anergy and Increased IL-10 Production Indicative of
Immune Tolerance
To examine whether active suppression may contribute to the
lack of detectable malaria blood stage antigen driven IFNc, IL-2,
IL-5, and/or IL-13 response in the exposed not sensitized group,
malaria antigen driven IL-10 production by CBMCs was also
examined in culture supernatants. IL-10 production in the
exposed not sensitized group was higher than in the other groups
(Figure 2). To determine whether malaria-specific anergy may also
contribute to the lack of T cell responses among the exposed not
sensitized newborns, cord blood from a subset of newborns (n=61)
was cultured in the presence of IL-2+IL-15 and malaria antigens
and compared to cultures with IL-2+IL-15 in the absence of
malaria antigens. In 21 of the exposed not sensitized children that
previously lacked detectable lymphocyte proliferation responses or
cytokine production, 11 (52%) had detectable antigen-specific
proliferative responses in the presence of IL-2+IL-15. By contrast,
malaria antigen with IL-2+IL-15 augmented four of 21 (19%) in
the exposed sensitized group and two of 17 (11%) in the not-
exposed children (Figure 3). This indicates the presence of
lymphocyte anergy in the exposed not sensitized group and
suggests immune tolerance.
Putatively Tolerant Offspring Are More Susceptible to
Malaria
During the follow-up period, malaria infection assessed by LM
was detected at least once in 42.9% (51/119) of exposed not
sensitized (putatively tolerant) children, 35.0% (86/246) of exposed
sensitized children, and 27.2% (58/217) of not-exposed children
(p=0.012). At least one malaria infection assessed by PCR was
observed in 67.2% (80/119), 64.2% (158/246), and 55.7% (121/
217) of these children, respectively (p=0.066). Since malaria
transmission can vary over time and location, and to adjust for
repeated measures on children, time, and location, we used a
generalized estimating equation to model infection status (Table 2).
Exposed not sensitized children had a 61% greater risk of infection
compared to not exposed children and 41% greater risk compared
to sensitized children. Similar trends were found for PCR
diagnosis: Exposed, not sensitized children had a 39% greater
risk of infection over time compared to sensitized children and
33% greater risk compared to not exposed children.
When parasite density was analyzed using a repeated measures
model, putatively tolerant children acquired an extra 1.30
Figure 2. Median malaria antigen-driven IL-10 production for
all subjects in the three experimental groups. Box-and-whisker
plots show median values, with the box indicating upper 75% and
lower 25% percentiles, and whiskers the 95% percentiles range.
Statistical differences were calculated with the Mann-Whitney U-test.
doi:10.1371/journal.pmed.1000116.g002
Figure 3. Augmentation of malaria-antigen driven lymphocyte
proliferation by CBMCs in a subset of exposed sensitized
(n=21), exposed not sensitized (n=21), and not exposed
(n=19) newborns in the presence of IL-2+IL-15. Values shown
are the fold-increase in cpm in cultures with IL-2+IL-15+malaria antigens
divided by cultures with IL-2+IL-15 alone. A positive response was
considered .2-fold increase (dashed horizontal line). Statistical
differences were calculated by Chi-square comparing the proportion
of positive responders. Solid horizontal bars indicate median values.
doi:10.1371/journal.pmed.1000116.g003
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(95%CI 1.05–3.01, p=0.032), compared to sensitized children,
assessed by LM or RTQPCR respectively every 6 mo, adjusted for
season and location. Parasitemia was similar among infected
individuals in the exposed sensitized, exposed not sensitized and
not-exposed groups, respectively (geometric mean parasitemia of
531, 643, and 437 parasites/ml by blood smear [p=0.77] and 770,
998, and 953 parasites/ml by RTQPCR [p=0.93]), indicating that
differences in the frequency of malaria infection account for much
of the difference in parasitemia between groups. Of note, when
parity was entered in the analysis, it was not associated with child
susceptibility to infection or parasitemia.
Putatively Tolerant Children Are at Greater Risk of
Anemia
To determine whether prenatal experience influenced the risk of
anemia, hemoglobin levels were measured over the period of
follow-up for offspring that were sensitized, putatively tolerant or
not exposed (Figure 4). Hemoglobin level for all children initially
declined with age then increased by 30–36 mo. Mean hemoglobin
levels in the exposed not sensitized group were consistently lower
than in the other two groups (Figure 4). To test whether
hemoglobin levels were significantly different between the groups
we used a mixed linear model that adjusts for repeated measures
over the period of observation and also adjusts for coinfections
with schistosomiasis, lymphatic filariasis and/or hookworm, as
well as height and weight measurements (body mass index [BMI],
a surrogate for nutritional status) from each follow-up. The mean
(6SD) adjusted hemoglobin levels for the putatively tolerant group
were 8.660.24 g/dl compared to the sensitized group
(9.160.19 g/dl, p=0.03) or the unexposed group (9.260.15 g/
dl, p=0.01).
The Relationship of Fetal Immune Experience with
Malaria-Specific B and T Responses in Childhood
In order to understand the immunologic basis for the increased
susceptibility of putatively tolerant offspring to malaria, we
examined how prenatal exposure would affect the child’s
subsequent acquisition of cellular and humoral immune responses.
A positive cellular response was defined as one or more cytokines
and/or lymphocyte proliferation response to the malaria antigen
or peptide, as indicated in the Methods section. Using a repeated
measures model, we observed 64% to 72% lower proportion of
exposed not sensitized (putatively tolerant) children produced
IFNc or IL-2, and/or showed lymphocyte proliferation to MSP1,
PfP0, and EBA175 by PBMCs, compared to sensitized children
during the period of follow-up (Figure 5A). These impaired
antigen-specific Th1-type responses in putatively tolerant children
were malaria-specific, since tetanus toxoid (TT)-driven IFNc, IL-2,
and/or lymphocyte proliferation responses were comparable
between the three groups. Generally, if a child failed to generate
a Th1-type recall response to malaria blood stage antigens at one
time during infancy, they also failed to do so during other follow-
up assessments. By contrast, 38% to 67% higher proportion of
putatively tolerant children produced more antigen-driven IL-10
during the period of follow-up compared to the other two groups
(Figure 5B). There was no difference in the proportion of
children’s PBMCs that produced IL-5 and/or IL-13 to MSP1,
PfP0, and/or EBA175 between the three groups (Figure 5C). In
summary, putatively tolerant newborns have an impaired malaria-
specific Th1-type cytokine response, a reciprocal increase in
antigen-driven IL-10 production, and a similar Th2-type cytokine
release, when compared to other children, and these differences
persist through early childhood.
There was no difference in the proportion (nor levels,
unpublished data) of children that acquired IgG antibody
responses to MSP142, or AMA1 with increasing age between the
three study groups as determined from 12 mo of age (Figure 6).
Both alleles (3D7 and FVO) for MSP142 and AMA1 were tested
and showed similar age-related patterns of response. By contrast,
tolerant children failed to acquire any antibody response to
EBA175 until 3 y of age (Figure 6). Antibody responses to PfP0
Table 2. Association of prenatal immune experience with susceptibility to P. falciparum infection in early childhood.
Group P. falciparum Infection Frequency
a
Longitudinal Analysis Accommodating Repeated Measures
b: Relative Risk of
Exposed Not Sensitized to Other Groups
LM PCR LM, Relative Risk (95% CI) PCR, Relative Risk (95% CI)
Exposed, not sensitized 0.213 0.412 — —
Exposed, sensitized 0.175 0.363 1.41 (0.97–2.07); p=0.074 1.39 (0.99–1.98); p=0.053
Not exposed 0.123 0.317 1.61 (1.10–2.43); p=0.024 1.33 (0.95–1.89); p=0.097
aValues indicate the population mean of the ratio of a positive result to total observations for each individual. The average number of observations for each group is
shown in Figure 1.
bGeneralized estimating equation adjusted for location, time, and repeated measures as described more fully in the Methods section.
doi:10.1371/journal.pmed.1000116.t002
Figure 4. Exposed not sensitized children at birth show
reduced mean hemoglobin levels throughout 36 months of
follow-up. The overall mean hemoglobin levels in exposed not
sensitized (putatively tolerant) children were significantly lower than
the exposed sensitized (p=0.03) and not exposed children (p=0.01)
based on a repeated measures model (described in Table 2). Analysis
was adjusted for children’s height and weight (BMI) and helminth
coinfection.
doi:10.1371/journal.pmed.1000116.g004
Prenatal Exposure and Malaria Risk
PLoS Medicine | www.plosmedicine.org 7 July 2009 | Volume 6 | Issue 7 | e1000116were not measured, as properly folded recombinant protein was
unavailable. Notable was the high proportion of mothers with
antibodies to each of the recombinant proteins at delivery in which
the antibodies were successfully transferred to their offspring. Of
note, antibody levels dropped dramatically by 6 mo of age and
then slowly increased over time (Figure 6). Generally if a mother or
child had an antibody response to one recombinant antigen, they
had a response to the other allele or recombinant antigens
measured, although this was not always the case.
Discussion
Results from the current study support the hypothesis that fetal
malaria experience contributes to regulation of childhood malaria
immunity in endemic areas where infection during pregnancy is
common. We first described a subset of children whose mothers
are infected with malaria in late pregnancy, but whose cord blood
lymphocytes obtained at delivery failed to produce common T cell
cytokines to several malaria blood stage antigens. We speculate
that these children are likely to be exposed to malaria blood stage
antigens in utero, but generate an immune phenotype that we
refer to as putatively tolerant. This immune tolerant phenotype is
based on the observation that approximately 90% of these
children consistently failed to generate specific malaria blood
stage antigen–induced Th1-type cytokine responses, compared
with approximately 50% of other children, even though the risk of
infection tended to be higher in the immune tolerant group.
Further, these immune tolerant children showed increased malaria
antigen–driven IL-10 production by cord blood lymphocytes that
persisted through childhood, suggesting the presence of T
regulatory cells specific for malaria blood stage antigens [46].
Although the current study did not show whether the malaria
Figure 5. The association of prenatal malaria exposure with the frequency of malaria antigen and tetanus toxoid-driven cytokine
production measured biannually to 36 months of age. (A) Exposed not sensitized children have a lower frequency of IFNc and IL-2 production,
and/or lymphocyte proliferation by PBMCs (a positive response is defined in the text andmethod section) compared to exposed sensitized children and
not-exposed children using a generalized estimating equations that adjusts for time, location, and repeated measures as more fully described in the
Methods section (relative risk, [95% confidence interval], exposed not sensitized children compared to exposed sensitized children: 0.28 [0.15–0.37],
p=0.0003 for MSP1; 0.33 [0.20–0.51], p=0.0008 for PfP0; 0.36 [0.19–0.74], p=0.005 for EBA175; and 1.07 [0.89–1.65] for tetanus toxoid). Similar effect
sizes were observedfor exposednotsensitized childrencomparedtonotexposedchildren (unpublisheddata).(B)Thefrequency ofantigen-drivenIL-10
is higher in the exposed not sensitized children than in exposed sensitized (relative risk for MSP1, 1.67 [1.35–2.73], p=0.0007; for PfP0 1.45 [1.03–2.51],
p=0.02; for EBA175 1.38 [0.99–2.42], p=0.05; and for tetanus toxoid 1.04 [0.85–1.12], p=0.73. (C) The frequency of malaria antigen-induced IL-5 and/or
IL-13 cytokine responses areequivalent for the three groups (relative risk for exposed not sensitized compared to exposed sensitized children: for MSP1,
0.97[0.79–1.21], p=0.35; for PfP0 0.92 [0.73–1.36], p=0.47; for EBA175, 0.83 [0.64–1.09], p=0.16; andfor tetanus toxoid, 1.01 [0.93–1.06], p=0.61. Similar
effect sizes were observed for exposed not sensitized children compared to not exposed children (unpublished data).
doi:10.1371/journal.pmed.1000116.g005
Prenatal Exposure and Malaria Risk
PLoS Medicine | www.plosmedicine.org 8 July 2009 | Volume 6 | Issue 7 | e1000116antigen–driven IL-10 originated from T cells, we and others have
previously shown that malaria blood stage antigens stimulate IL-10
production by CD4
+ T cells in CBMCs from malaria-exposed
newborns and in PBMCs from children, but not in cells from
newborns in North America [15,47].
Further evidence for prenatal immune experience in the
putatively tolerant group is that antigen-specific proliferation
responses can be detected in over half of a randomly selected
subset of tolerant newborns following the addition of IL-2 and IL-
15, indicative of lymphocyte anergy [48,49]. The mechanisms for
immune hyporesponsiveness in this tolerant subset of children are
likely to be complex and involve multiple pathways. For example,




+ cells in cord blood of malaria infected
women that can suppress antigen-driven CD4
+CD25
dim cells
(Mackroth, et al., personal communication). Brustoski and
colleagues [46] also found increased IL-10 production by CBMCs
in response to malaria blood stage antigens, and they noted that
depleting CD4+CD25
bright cells abrogates parasite-specific IL-10
production and increases IFNc-specific responses, suggesting a
population of IL-10–secreting T regulatory cells in newborns.
Alternatively, there may be clonal deletion of malaria-specific
lymphocytes, as previously demonstrated in offspring of malaria-
infected mice [50] and in analogous studies of maternal exposure
to human filariasis [51].
An important consequence of this antenatally acquired immune
‘‘tolerance’’ is increased risk for malaria infection during
childhood. Prior studies have demonstrated that offspring of
women with placental malaria and/or malaria infection at delivery
are more likely to be infected with malaria [10,12]. However, the
basis for this increased risk has not been well defined and the
antenatal exposure to malaria not evaluated. The current study is
novel in that it takes an immunological approach to better define
antenatal experience with malaria and its effect on the infant’s
susceptibility to malaria.
A potential mechanism for this increased risk became apparent
when offspring of infected women were divided into groups of
children exposed to malaria in utero, in which immune priming to
malaria antigens resulted, and children potentially exposed to
malaria in utero but where evidence for immune priming by
CBMCs was lacking (termed putatively tolerant). Tolerant children
had a 61% and 34% higher incidence of malaria based on LM and
PCR, respectively, using a generalized estimating equation that
accommodates the individual correlation among repeated malaria
measurements, as compared to not exposed children [52]. This
difference is unlikely a consequence of differences in exposure, since
adjustments for location and time of season did not affect the
association. Thus putatively tolerant children appear to be more
susceptible to malaria infection compared to not exposed children.
This increased susceptibility may arise from prenatally acquired
Th1-type immune hyporesponsiveness that persists into childhood.
There was also a strong trend for putatively tolerant children to be
more susceptible to malaria compared to the exposed sensitized
children, although this relationship did not reach statistical
significance. This weaker association may have resulted from
misclassification of some sensitized children who may have had
more than one regulatory phenotype. The fetus is likely to acquire a
spectrum of immune responses to malaria blood stage antigens
during pregnancy, ranging from robust Th1-type immune respons-
es to fully immune regulatory phenotypes. Where the fetus resides
on this spectrum may depend on the type and amount of malaria
antigen exposure and when exposure occurs during gestation. Thus
the division between these two groups is not precise. Ultimately we
aim to identify one or more immune markers that better
characterize an immune regulatory phenotype, such that it can be
used as a continuous variable to predict susceptibility to malaria
infection and disease.
There was a stronger association with susceptibility to malaria
infection among the putatively tolerant group as measured by LM
compared to PCR diagnosis. This is not surprising since PCR can
detect more infections with low-level parasitemia, ones less likely to
result in overt clinical disease.
There are several potential mechanisms that may increase
susceptibility to malaria among tolerant children. The failure of
90% or more of tolerant children to acquire antigen-specific T
cells that produce a Th1-type cytokine profile during the first 3
years of life may result in inadequate T cell support for antibody
production and/or antibody-dependent cell mediated immunity.
Figure 6. The association of prenatal exposure to malaria with acquisition of MSP142 and AMA1, and EBA-175 specific IgG
responses in all children. There were no differences between the proportion of children with antibody responses to MSP142 and AMA1 between
the three groups beginning at 12 months of age as determined by a generalized estimating equation described in Figure 5 (exposed not sensitized
group compared to exposed sensitized group: relative risk for MSP142, 1.05 [0.88–1.17], p=0.457; for AMA1, 0.87 [0.74–1.11], p=0.251), but a
significant reduction for EBA-175–specific IgG, 0.41 [0.28–0.97], p=0.03. Similar effect sizes were observed for exposed not sensitized children
compared to not exposed children (unpublished data).
doi:10.1371/journal.pmed.1000116.g006
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to that observed in the other groups, as measured by the overall
proportion (and levels) of malaria-specific IgG directed toward
MSP142 and AMA1. It is possible that these measures do not
provide a good correlate of protective immunity, and more
restricted antibody responses may be involved. In this context,
immune tolerant children failed to acquire antibodies to EBA175
compared to other children, although the overall antibody
response to EBA175 was lower than to the other antigens. We
have also previously observed that tolerant children in the same
population had impaired functional antibody responses to MSP119
[16]. T cell help for antibody production may be intact among
putatively tolerant children, as indicated by the presence of a
frequency of Th2-type cytokine production by PBMCs similar to
that of other children. T cell–dependent effector mechanisms,
however, may be impaired. Parasite killing is augmented when
antibodies act in cooperation with monocytes [53–55] or other
FccR-bearing cells [56]. Optimal activation of monocytes or other
FccR-bearing cells requires T cell help through release of
cytokines such as IFNc and IL-2, which was diminished in
PBMCs of tolerant children during the follow-up period.
Putatively tolerant children were also at increased risk for
developing anemia, showing mean hemoglobin of 0.5 g/dl lower
during the follow-up period than children in the other groups.
Previous studies have shown that babies born to anemic mothers
(associated with malaria in pregnancy) are more susceptible to
anemia (perhaps due to reduced iron stores [57,58]). Indeed,
almost half of the women in putatively tolerant group were
primigravid compared to about a third in the other groups.
Unfortunately, reliable hemoglobin measurements were not
obtained in women at delivery, so we could not associate maternal
anemia with risk of anemia during childhood. Another contrib-
uting factor to greater anemia in the putatively tolerant group is
increased frequency of malaria infection, since the association with
lower hemoglobin levels is reduced if the analysis is adjusted for
malaria infection. This association was unlikely to be confounded
by co-infections with hookworm, schistosomiasis, and/or lym-
phatic filariasis, since these infections are uncommon (,5% in
children 3 years and younger in this population [34]). Poor
nutritional status is also an important risk factor for anemia.
Overall children in the cohort had good nutritional status. The
BMI for all children in the cohort fell above the third percentile at
each biannual follow-up visit, and most BMIs were within61S D
of the mean based on the recently published WHO standards for
developing countries [59]. The analysis was also adjusted for BMI
using the linear mixed model. The severity of anemia can be
influenced by the presence of sickle cell trait (HbAS) or alpha-
thalassemia. These alleles are present in coastal populations of
Kenyans at gene frequencies of approximately 0.13 and 0.14,
respectively [60]. Individuals in the population were not
genotyped, but there is no a priori reason that these genotypes
should be skewed among the prenatal exposure groups.
Why some offspring of malaria infected women acquire a
tolerant phenotype and others become primed to malaria antigens
cannot be directly evaluated; there are technological and ethical
limitations to understanding precisely when during gestation, or
for how long before parturition, the fetal innate or adaptive
immune response might be affected by exposure to maternal
malaria. Consistent with the concept that in utero exposure to
malaria is linked with placental sequestration of infected
erythrocytes, we noted that a greater proportion of women whose
offspring were deemed tolerant were primigravida mothers (49%),
relative to mothers with sensitized offspring (37%) and unexposed
women and newborns (32%). This observation suggests that the
amount or duration of malarial antigen exposure, or time of
exposure during gestation, may determine whether a fetus
becomes tolerant or sensitized. It is possible that some tolerant
newborns may not have been exposed to malaria antigens during
gestation, even though the mother was infected. This possibility is
hard to exclude, although our preliminary data suggest that MSP1
is commonly found in cord blood from infected women, often as
immune complexes ([31] and unpublished data). Indeed, these
immune complexes may facilitate the transplacental transport of
malarial antigens (May, et al., personal communication), similar to
transplacental antigen transport demonstrated for tetanus toxoid
[61] and nonhuman insulin [62]. The types of malarial antigens
that cross the placenta may also determine whether tolerance or
priming occurs [63]. Fetal antigen-presenting cells (APCs) are not
fully mature and provide weak costimulation to T cells compared
to adult APCs [64]. If the fetus is exposed only to soluble proteins,
tolerance may be induced in the form of T cell anergy, as indicated
in the current study. However, if the fetus is also exposed to
molecules that induce strong innate immune responses (such as
parasite DNA, which we have detected in about 10% of cord
blood samples [31]), this could sufficiently activate fetal APCs to
prime T cells.
There are several limitations in this study. First, children were
only followed biannually for the presence of malaria infection and
hemoglobin levels, so malaria infections occurring between
sampling times would be missed. Second, mothers were only
assessed for malaria at delivery and placental histopathology was
not available. Uninfected women at delivery may have been
infected earlier during pregnancy. This would have misclassified
some putatively tolerant children as not exposed. The effect on the
study would be to reduce the observed differences between the
tolerant and not-exposed groups. Some children died during the
first year after birth and were not included in the cohort. We were
able to ascertain seven deaths, but could not determine whether
these children died of malaria or not. This could introduce a bias
into the results. Finally, the presence of clinical malaria in children
was not examined. This omission reduces our ability to assess
whether fetal immune tolerance protects against symptomatic
malaria by modulating the host inflammatory response. This
possibility is suggested by reports of asymptomatic malaria in
children over 6 months of age that had been closely followed since
birth [40]. Studies are currently underway to address these
limitations.
Once the significance of fetal malaria experience is better
understood, it should translate into more effective strategies for
malaria chemoprophylaxis during pregnancy. Malaria chemopro-
phylaxis that completely prevents infection during pregnancy, for
example, may reduce fetal exposure, thereby preventing the
development of immune tolerance. If this reduces both the risk of
infection and disease in offspring, then such treatment would be
desirable. However, if fetal immune tolerance reduces the risk of
clinical disease, then prenatal chemoprophylaxis should be
targeted to limiting disease and not infection per se, and linked
with intermittent presumptive antimalarial chemoprophylaxis
during infancy.
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Background. Each year,Plasmodiumfalciparum,a mosquito-
borne parasite, causes about 500 million cases of malaria and
about one million people die as a result. Most of these deaths
occur in young children in sub-Saharan Africa. Indeed, malaria
accounts for a fifth of all childhood deaths in Africa, which
makes it one of the most important childhood infectious
diseases in this region. Very young children—those up to 6
months old—are relatively resistant to high-density
parasitaemia and to clinical malaria, but children between 6
and 36 months old have an increased susceptibility to
parasitaemia and to clinical malaria. Parasitaemia is the
presence of P. falciparum parasites in the blood; a high
density of blood-stage parasites causes the symptoms of
clinical malaria (including high fever) and life-threatening
organ damage and anemia (a lack of red blood cells).
Why Was This Study Done? The age-dependent pattern
of susceptibility to malaria suggests that young babies are
protected by antibodies provided by their mothers, but that
by 6 months old, when these antibodies have largely
disappeared, babies have not yet fully developed their own
anti-malaria immunity. However, little is known about the
acquisition of anti-malaria immunity in infants, a process that
needs to be understood in order to design effective vaccines
for this age group. In particular, it is unclear how maternal
malaria infection affects the acquisition of anti-malaria
immunity. Malaria in pregnancy may expose the unborn
child to malaria-infected red blood cells and to soluble malaria
antigens (molecules that the immune system recognizes as
foreign). This exposure could increase or decrease the child’s
immune responses to blood-stage malaria antigens and thus
affect his/her ability to fight off malaria. In this study, the
researchers investigated how prenatal malaria exposure
affects anti-malaria immunity in young children and their
susceptibility to subsequent malaria infections.
What Did the Researchers Do and Find? Theresearchers
determined which of 586 newborn babies enrolled into their
study in an area of Kenya where malaria is very common had
been exposed to P. falciparum before birth by looking for
parasites in their mother’s blood at delivery. They looked for
malaria-specific immune responses in T cells (a type of
immune system cell) in the newborn babies’ cord blood by
measuring the production of cytokines (molecules that either
activate or inhibit the immune system) by these cells after
exposure to malaria antigens. Finally, they examined the
infants twice yearly for 3 years for malaria infection, malaria-
specific immune responses, and anemia. The researchers
classified the babies into three groups; cord blood cells of
‘‘sensitized’’ babies made activating cytokines in response to
malaria antigens; cord blood cells of ‘‘exposed, not-sensitized’’
babies did not make activating cytokines but made an
inhibitory cytokine (IL-10); and ‘‘not-exposed’’ babies were
born to mothers with no P. falciparum infection at delivery. In
their first 3 years of life, the exposed, not-sensitized group had
a 60% greater risk of malaria infection (measured by counting
parasites in their blood) than the unexposed group and a
slightly higher risk of malaria infection than the sensitized
group. They also had lower hemoglobulin levels (a sign of
anemia) than the other babies. At age 6 months, the T cells of
exposed, not-sensitized children were less likely to make
activating cytokines in response to malaria antigens but made
more IL-10 than the T cells of the other children; malaria-
specific antibody levels were similar in the three groups.
What Do These Findings Mean? These findings suggest
that some children who are exposed to malaria before birth
become ‘‘tolerant’’ to blood-stage malaria antigens.
Exposure to malaria antigens before birth ‘‘tricks’’ their T
cells into recognizing these antigens as self antigens. This
immune tolerance, which persists into childhood, reduces
the ability of the immune system to attack and destroy
parasites and increases the susceptibility of these tolerant
children to malaria infection. Why some children who are
exposed to malaria before birth become tolerant while
exposure to malaria antigens ‘‘primes’’ the immune system
of other children to respond efficiently to these antigens is
not clear. However, these findings could have important
implications for the design of malaria vaccines for use in
areas where children are often exposed to malaria before
birth and for the design of strategies for the prevention of
malaria during pregnancy.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000116.
N This study is further discussed in a PLoS Medicine
Perspective by Lars Hviid
N Information is available from the World Health Organiza-
tion on malaria (in several languages)
N The US Centers for Disease Control and Prevention
provides information on malaria (in English and Spanish)
N Information is available from the Roll Back Malaria
Partnership on all aspects of global malaria control,
including information on malaria in pregnancy and on
children and malaria
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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